Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients
Status:
NOT_YET_RECRUITING
Trial end date:
2034-12-09
Target enrollment:
Participant gender:
Summary
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer immunotherapeutic (PCI) strategy with or without CD8-selective IL-2 mutein fusion protein in patients with triple negative breast cancer undergoing neoadjuvant chemoimmunotherapy.